DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/7wpkdd/drg_insight) has announced the addition of Decision Resources, Inc's new report "DRG Insight: Colorectal Cancer (G7)" to their offering.
DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives. Colorectal cancer (CRC) is one of the most common forms of cancer and in 2010 was the fifth most common cancer-related death worldwide.
Over the next ten years the number of incident cases of CRC will increase as the aging population continues to expand and patients continue to be identified through screening efforts throughout the major markets.
Although in 2010 major-market sales of CRC treatments totaled more than $7 billion, reflecting robust sales of premium-priced products, interviewed experts express the demand for more treatments that address CRC patients' numerous unmet needs.
Key Topics Covered:
Current Market Landscape
Etiology & Pathophysiology
Select Drug Targets
Growth Drivers & Constraints
Country Specific Decision Trees
Comparison of Key Agents
Expert Insight on Prescribing Trends
Importance of Drug Attributes in Prescribing Decisions
Pricing & Reimbursement
Factors Influencing Pharmacy Director Tier Placement Decisions
Accessibility and Cost Hurdles
Unmet Needs, Emerging Therapies
Important Endpoints in Prescribing Decisions,
2010 and 2010 sales and Market Share
For more information visit http://www.researchandmarkets.com/research/7wpkdd/drg_insight
Source: Decision Resources, Inc
Source: Research and Markets